ELIZABETH GOODWIN: Open Payments
NPI 1306834064 · CLEVELAND, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,583 in 111 payments from 21 companies in 2025. Trend: 2023 $1,937 · 2024 $2,876 · 2025 $2,583
Food & beverage: $2,506Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $752 |
| Janssen Biotech, Inc. | 17 | $437 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $270 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $240 |
| Novo Nordisk Inc | 2 | $158 |
| Madrigal Pharmaceuticals | 5 | $126 |
| Aimmune Therapeutics, Inc. | 5 | $115 |
| Lilly USA, LLC | 4 | $75 |
| Celltrion USA Inc. | 3 | $72 |
| Intercept Pharmaceuticals, Inc. | 3 | $61 |
Products named: TREMFYA, LINZESS, XIFAXAN, ENTYVIO, SKYRIZI, REZDIFFRA, Wegovy, ZENPEP.
Industry payments across TN — which companies pay providers there.
